Payment overview · 2025
General Payments
$564.63
26 reported records · 8 companies
Healthcare provider profile · identity verified
Dutsi Behm, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1982780078
Verified facts
What the public records show
CMS Open Payments records show Dutsi Behm, M.D. received $564.63 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.67 | 25.3% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.45 | 17.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.29 | 15.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.80 | 10.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.60 | 10.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.91 | 9.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.58 | 7.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.33 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $564.63 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $107.84 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $97.45 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $88.29 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $81.17 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $59.60 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 61 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
61 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 225 |
| Losartan Potassium | Losartan Potassium | 337 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 94 |
| Metformin Hcl | Metformin Hcl | 298 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 56 |
| Gabapentin | Gabapentin | 192 | 63 |
| Omeprazole | Omeprazole | 191 | 74 |
| Simvastatin | Simvastatin | 188 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 175 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 70 |
| Chlorthalidone | Chlorthalidone | 160 | 49 |
| Azithromycin | Azithromycin | 146 | 109 |
| Montelukast Sodium | Montelukast Sodium | 138 | 58 |
| Torsemide | Torsemide | 123 | 41 |
| Eliquis | Apixaban | 118 | 26 |
| Synthroid | Levothyroxine Sodium | 118 | 30 |
| Azelastine Hcl | Azelastine Hcl | 116 | 87 |
| Telmisartan | Telmisartan | 114 | 33 |
| Furosemide | Furosemide | 112 | 38 |
| Famotidine | Famotidine | 110 | 61 |
| Carvedilol | Carvedilol | 106 | 26 |
| Meloxicam | Meloxicam | 106 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 31 |
| Glimepiride | Glimepiride | 97 | 28 |
| Enalapril Maleate | Enalapril Maleate | 94 | 27 |
| Prednisone | Prednisone | 87 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 23 |
| Labetalol Hcl | Labetalol Hcl | 81 | 25 |
| Alprazolam | Alprazolam | 68 | 25 |
| Januvia | Sitagliptin Phosphate | 68 | 20 |
| Creon | Lipase/Protease/Amylase | 61 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 22 |
| Amoxicillin | Amoxicillin | 54 | 43 |
| Bumetanide | Bumetanide | 51 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 17 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Ramipril | Ramipril | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | 14 |
| Celecoxib | Celecoxib | 47 | 21 |
| Meclizine Hcl | Meclizine Hcl | 47 | 19 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Lactulose | Lactulose | 43 | 15 |
| Repaglinide | Repaglinide | 43 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 43 | 18 |
| Allopurinol | Allopurinol | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Linzess | Linaclotide | 41 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 21 |
| Ozempic | Semaglutide | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | 13 |
| Lorazepam | Lorazepam | 39 | 15 |
| Lisinopril | Lisinopril | 38 | 14 |
| Atenolol | Atenolol | 36 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 23 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Captopril | Captopril | 21 | suppressed |
| Naproxen | Naproxen | 21 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Benicar | Olmesartan Medoxomil | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $564.63 · 26 records | ABBVIE INC. | AIRSUPRA, CREON, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VOWST, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error